Our previous research obtained purified recombinant porcine interferon-α (rPoIFN-α) containing thioredoxin (Trx) fusion tag in E. coli Rosetta (DE3). Here, we evaluate the efficacy of this rPoIFN-α to prevent piglets from the infection of the transmissible gastroenteritis virus (TGEV) attack. In this experiment, twenty-five TGEV-seronegative piglets were randomly divided into five groups. Group 1 was positive control and only challenged with TGEV; Pigs in groups 2–4 were pretreated with 2 × 10(7)IU/pig, 2 × 10(6)IU/pig, and 2 × 10(5)IU/pig rPoIFN-α before TGEV challenge. The fifth group is a negative control group. The animals of this group are pretreated only with Trx protein-containing PBS solution without TGEV challenge. After 48 h of rPoIFN-α pretreatment, the pigs in groups 1–4 were challenged by TGEV, and the pigs in group 5 were administered with PBS. The surveillance results show that Pigs pre-treated with 2 × 10 (7) IU/pig rPoIFN-α are fully aligned with the violent TGEV attack. Pigs pretreated with 2 × 10 (6) IU/pig rPoIFN-α are partially aligned with the violent TGEV attack. Though piglets pretreated with 2 × 10(6) IU/pig or 2 × 10(5)IU/pig rPoIFN-α cannot be adapted to the challenge of TGEV. However, the use of this dose of rPoIFN-α could put off the clinical signs of pigs than the positive control group of the above. These results indicate that rPoIFN-α can protect pigs from the infection of potential TGEV or delay the appearance of clinical symptoms, and its effect is dose-dependent.

我们先前的研究获得了在大肠杆菌Rosetta（DE3）中含有硫氧还蛋白（Trx）融合标签的纯化重组猪干扰素-α（rPoIFN-α）。在这里，我们评估了这种rPoIFN-α预防小猪受到传染性胃肠炎病毒（TGEV）攻击的感染的功效。在该实验中，将25只TGEV血清阴性的仔猪随机分为5组。第1组为阳性对照，仅用TGEV攻击；TGEV攻击前，第2-4组的猪用2×10（7）IU /猪，2×10（6）IU /猪和2×10（5）IU /猪rPoIFN-α预处理。第五组是阴性对照组。该组动物仅用含Trx蛋白的PBS溶液预处理，而无TGEV攻击。rPoIFN-α预处理48小时后，第1-4组的猪受到TGEV攻击，第5组猪给予PBS。监测结果表明，用2×10（7）IU /猪rPoIFN-α预处理的猪与剧烈的TGEV攻击完全吻合。用2×10（6）IU /猪rPoIFN-α预处理的猪与剧烈的TGEV攻击部分对准。尽管用2×10（6）IU /猪或2×10（5）IU /猪预处理的仔猪rPoIFN-α不能适应TGEV的挑战。但是，与上述阳性对照组相比，使用该剂量的rPoIFN-α可以延缓猪的临床症状。这些结果表明rPoIFN-α可以保护猪免受潜在TGEV的感染或延迟临床症状的出现，并且其作用是剂量依赖性的。用2×10（6）IU /猪rPoIFN-α预处理的猪与剧烈的TGEV攻击部分对准。尽管用2×10（6）IU /猪或2×10（5）IU /猪预处理的仔猪rPoIFN-α不能适应TGEV的挑战。但是，与上述阳性对照组相比，使用该剂量的rPoIFN-α可以延缓猪的临床症状。这些结果表明rPoIFN-α可以保护猪免受潜在TGEV的感染或延迟临床症状的出现，并且其作用是剂量依赖性的。用2×10（6）IU /猪rPoIFN-α预处理的猪与剧烈的TGEV攻击部分对准。尽管用2×10（6）IU /猪或2×10（5）IU /猪预处理的仔猪rPoIFN-α不能适应TGEV的挑战。但是，与上述阳性对照组相比，使用该剂量的rPoIFN-α可以延缓猪的临床症状。这些结果表明rPoIFN-α可以保护猪免受潜在TGEV的感染或延迟临床症状的出现，并且其作用是剂量依赖性的。